Quick Takeaways
- MPM BioImpact LLC filed SCHEDULE 13G/A for Context Therapeutics Inc. Common Stock, par value $0.001 per share (CNTX).
- Disclosed ownership: 12%.
- Date of event: 31 Dec 2025.
MPM BioImpact LLC - 31 Dec 2025 SCHEDULE 13G/A Report for Context Therapeutics Inc. Common Stock, par value $0.001 per share (CNTX)
- Filing Manager
- MPM BioImpact LLC
- Reporting Manager
- MPM BioImpact LLC
- Symbol
- CNTX
- Shares outstanding
- 92,063,716 shares
- Disclosed Ownership
- 10,679,391 shares
- Ownership
- 12%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 16:09:28 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 08 Jan 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MPM BioImpact LLC disclosed 12% ownership in Context Therapeutics Inc. Common Stock, par value $0.001 per share (CNTX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 08 Jan 2025.
- Current filing was accepted on 17 Feb 2026, 16:09.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| MPM BioImpact LLC | 12% | 10,679,391 | 10,679,391 | 0 | Christopher Wolf | Chief Financial Officer |